NVCT NASDAQ
Nuvectis Pharma, Inc.
1W: -12.1%
1M: +24.0%
3M: +29.3%
YTD: +28.6%
1Y: +2.7%
3Y: -35.3%
$10.35
-0.59 (-5.39%)
Weekly Expected Move ±12.6%
$8
$10
$11
$12
$14
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$274.5M
52W Range5.55-13.34
Volume156,786
Avg Volume71,837
Beta-0.12
Dividend—
Analyst Ratings
Company Info
CEORon Bentsur
Employees13
SectorHealthcare
IndustryBiotechnology
IPO Date2022-02-04
Websitenuvectis.com
1 Bridge Plaza
Fort Lee, NJ 07024
US
Fort Lee, NJ 07024
US
201 614 3150
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Latest News
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Shemesh Shay | A-Award | 150,000 | — | 2026-01-06 |
| BENTSUR RON | A-Award | 150,000 | — | 2026-01-06 |
| Poradosu Enrique | A-Award | 150,000 | — | 2026-01-06 |
| Carson Michael J. | A-Award | 61,200 | — | 2026-01-06 |
| BENTSUR RON | P-Purchase | 5,000 | $5.72 | 2025-11-05 |